• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Elan to proceed with formal sale process

Elan to proceed with formal sale process

June 14, 2013
CenterWatch Staff

Elan has announced it is proceeding with a formal sale process in light of the expressions of interest received to date. As part of this process, Royalty Pharma will be invited to participate. Elan has urged shareholders not to tender into the current Royalty Pharma offer.

Elan said its board and management are aligned in maximizing the full value potential of the business on behalf of its shareholders. Shareholders are scheduled to meet Monday to vote on the company’s recent M&A deals. Elan’s board has unanimously rejected Royalty Pharma’s sweetened offer of $13 per share in cash plus contingent value rights linked to future performance of MS drug Tysabri, for a potential value of $8 billion.

The four transactions on Monday’s agenda are: Elan’s $1 billion cash acquisition of a 21% stake in South San Francisco-based Theravance’s royalties from the respiratory franchise it shares with GSK; Elan’s acquisition of Vienna, Austria-based AOP Pharmaceuticals for $348.8 million; the spinout of ELND005 into a new Irish startup Speranza Therapeutics, with $70 million in funding; and a $200 million share buyback.

 Separately, Royalty Pharma on Friday asked Elan ordinary shareholders to vote against all four resolutions. If any of the items are approved, the Irish Takeover Panel will require Royalty to withdraw its offer and may prevent Royalty from making another unsolicited offer for 12 months.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing